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Background: Cancer-specific hypermethylation of (promoter) CpG islands is common during the tumorigenesis of
colon cancer. Although associations between certain genetic aberrations, such as BRAF mutation and microsatellite
instability, and the CpG island methylator phenotype (CIMP), have been found, the mechanisms by which these
associations are established are still unclear. We studied genome-wide DNA methylation differences between
colorectal tumors carrying a BRAF mutation and BRAF wildtype tumors.
Results: Using differential methylation hybridization on oligonucleotide microarrays representing 32,171 CpG-rich
regions, we identified 1,770 regions with differential methylation between colorectal tumor and paired normal
colon. Next, we compared the tumor/normal methylation ratios between different groups of patients. Related to
CIMP, we identified 749 differentially methylated regions, of which 86% had a higher tumor/normal methylation
ratio in the CIMP-positive group. We identified 758 regions with a BRAF mutation-specific methylation change, of
which 96% had a higher tumor/normal methylation ratio in the BRAF mutant group. Among the genes affected by
BRAF mutation-specific methylation changes, we found enrichment of several cancer-related pathways, including
the PI3 kinase and Wnt signaling pathways. To focus on genes that are silenced in a tumor-specific rather than a
lineage-specific manner, we used information on the epigenetic silencing mark H3K27me3 in embryonic stem (ES)
cells. Among the genes showing BRAF mutation-specific promoter methylation but no H3K27me3 mark in ES cells
were forkhead box (FOX) transcription factors associated with the PI3 kinase pathway, as well as MLH1 and SMO.
Repression of FOXD3 gene expression in tumors could be related to its promoter hypermethylation.
Conclusions: We identified new BRAF mutation-specific methylation changes in colorectal cancer. Epigenetic
downregulation of these targets may contribute to mutationally active BRAF-driven tumorigenesis, explaining its
association with aberrant DNA methylation.
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The CpG island methylator phenotype (CIMP) was
introduced in 1999 by Toyota et al. to describe a subset
of colorectal tumors with high levels of cancer-specific
methylation [1]. Subsequent studies regarding CIMP in
colon cancer described a strong association between this
epigenetic phenotype, BRAF mutations, and microsatel-
lite instability (MSI) [2-8]. As sporadic MSI colon cancer* Correspondence: j.m.boer@erasmusmc.nl
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reproduction in any medium, provided the oris caused by promoter methylation of a mismatch repair
gene (MLH1, MSH2, or MSH6) the association between
MSI and the high levels of DNA methylation in CIMP is
considered a causative one [9,10]. However, the associ-
ation between activating BRAF mutations and CIMP
remains unclear.
The field of epigenetic research has progressed from a
candidate-gene to a genome-wide approach, which not only
provides a plethora of new candidate targets of cancer-
specific DNA methylation but also a better understanding
of transcription regulation by DNA methylation [11]. Using
such genome-wide DNA methylation approaches could
help to identify new targets of BRAF mutation-specific pro-
moter methylation. Hinoue et al. [2] examined the CIMP-ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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CpG sites, located at 807 genes, in 235 primary colorectal
tumors and discovered specific methylation of genes medi-
ating various signaling pathways involved in colon cancer
tumorigenesis. In this study, we screened 32,171 CpG sites
located at 10,537 genes in a selected cohort of 19 patients
with right-sided colon cancer to obtain additional insight
into the association between BRAF mutations and DNA
methylation in colon cancer tumorigenesis. Recent studies
have described a gradual increase in CIMP and BRAF mu-
tation prevalence from the rectum to the ascending colon
[12,13]. To avoid tumor location as a factor that could pos-
sibly influence the levels of methylation, we specifically
studied tumors originating from the ascending colon and
cecum. The frequency of BRAF mutations in the CIMP-
positive patients was comparable to those previously
described in larger cohort studies [2,8,14,15].
Recent publications have reported a possible pre-
marking of cancer-specific hypermethylated genes by the
inactivation mark histone H3 lysine 27 trimethylation
(H3K27me3) and binding of the polycomb group member
SUZ12 in both ES cells and differentiated normal colon
mucosal tissue [16-18]. These studies led to the suggestion
that colon cancer cells utilize a pre-existing repression pro-
gram to target loci for cancer-specific promoter methyla-
tion [16,18-20]. However, the presence of such repressive
histone modifications at promoters during differentiation
from ES to normal colon epithelium suggests that the asso-
ciated genes are at a transcriptional silent state prior to
tumor formation, reducing the relevance of the DNA
methylation of pre-marked genes to tumorigenesis. In an
attempt to identify biologically relevant BRAF mutation-
specific promoter methylation, we excluded loci with
H3K27me3 pre-marking in ES cells from the functional
pathway analyses. By both extending the number of
screened loci and filtering out pre-marked genes, we iden-
tified new targets of BRAF mutation-specific methylation
that could either create a favorable setting for the acquisi-
tion of BRAF mutations or function as an addition to up-
regulation of the RAS-RAF-MEK pathway.
Results
Colon cancer-specific CpG island methylation
We identified 1,770 CpG-rich regions with significant
methylation differences between tumor and paired nor-
mal colon. Of these, 1,234 differentially methylated
regions were associated with 816 genes, of which 531
were localized to gene promoters (Additional file 1). As
expected, CpG islands were mostly found hypermethy-
lated in tumors (78.8%) [11].
We compared our results with those of Irizarry et al.
[11], who described 2,707 cancer-specific differentially
methylated regions based on the comparison of 13 colo-
rectal cancer tumor-normal pairs. Of the describeddifferentially methylated regions, 1,203 overlapped with
our CpG island array regions, of which 282 (23%) were
also differentially methylated between tumor and normal
in our analysis. This overlap is reasonable, considering
the different, modest-sized patient groups, and different
experimental approaches.
CIMP-specific methylation
Next, we compared the tumor/normal methylation ratios
between different groups of patients. Between CIMP-
positive (n = 11) and CIMP-negative (n = 8) patients, 749
CpG-rich regions showed methylation changes, of which
85.6% had a higher tumor/normal methylation ratio in the
CIMP-positive group. Of these differentially methylated
regions, 589 were associated with 508 genes, of which 244
were localized to gene promoters (Additional file 2). In 8
out of 11 CIMP-positive tumors, promoter methylation of
MLH1, the cause of microsatellite instability in sporadic
colon cancer, was observed, which was consistent with
methylation-specific PCR (Additional file 3). We conclude
that the hypermethylation in specific genomic regions
used to define CIMP [6] is associated with methylation
changes throughout the genome.
BRAF mutation-specific methylation
Activating BRAF mutations have been associated with
high levels of CpG island methylation and MSI in colon
cancer [2-8]. To investigate this association, we com-
pared the tumor/normal methylation ratio profiles of
BRAF wildtypes (n = 11) with those containing the
BRAFV600E mutation (n = 8). We identified 758 regions
with a BRAF mutation-specific methylation change, of
which 96.3% had a higher tumor/normal methylation
ratio in the BRAF mutant group. Out of these 758
regions, 579 were associated with 479 genes, of which
229 were localized to gene promoters (Additional file 4).
Since BRAF mutations and CIMP co-occurred in eight
samples, as expected from other studies [8,14,15], there
was a high level of overlap between CIMP- and BRAF
mutation-specific methylation changes (Figure 1A). Com-
parable levels of overlap were found, focusing on promoter
regions only (data not shown).
Regions with methylation changes are enriched for
inactive chromatin marks
Regions binding the polycomb repressor complex 2
(PRC2) component SUZ12 in ES cells were found to be
enriched among the loci differentially methylated between
colon cancer and normal colon (Table 1). The histone
mark H3K27me3 is mediated by the PRC2 complex [21],
and the two marks have been reported to be highly corre-
lated [17]. Enrichment of ES cell H3K27me3 binding
regions among the regions with colon cancer-associated
methylation changes was, therefore, expected and was
Figure 1 Proportional Venn diagrams showing the overlap
between BRAF mutation- (blue) and CIMP-specific (yellow)
methylation changes (A) for all CpG-rich regions and (B) for
promoter regions filtered for H3K27me3 binding in embryonic
stem cells.
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mutation-associated differential methylation changes were
also highly enriched for regions binding SUZ12 and
H3K27me3 in ES cells (Table 1). Additionally, sites binding
CTCF and the active chromatin mark H3K4me3 were
underrepresented among the differentially methylated
regions. Interestingly, although all colon cancer-, CIMP-,
and BRAF mutation-specific differentially methylated
regions are underrepresented for H3K4me3, this depletion
is most evident for BRAF mutation-specific regions.
After exclusion of regions with H3K27me3 pre-marking in
ES cells, the overlap between CIMP- and BRAF mutation-
specific methylation changes for all loci (not shown) andTable 1 Overlap between regions with methylation changes i
Total SUZ12 Pa H3
Colon tumor regions 1,770 540 (30.5%) 0 561
Remaining regions 30,401 3,447 (11.3%) 3,33
CIMP-specific regions 749 160 (21.4%) 0 169
Remaining regions 31,422 3,827 (12.2%) 3,72
BRAF-specific regions 758 171 (22.6%) 0 180
Remaining regions 31,413 3,816 (12.1%) 3,71
aP values are those for the χ-squared test.promoters (Figure 1B) remained highly significant. Despite
this high level of overlap, approximately 50% of BRAF
mutation-specific methylation changes showed no overlap
with CIMP. In our functional analysis, we focused on all
promoter regions with BRAF mutation-specific methylation
changes, regardless of overlap with CIMP.
BRAF mutation-associated methylation pathway analysis
To identify biological pathways affected by BRAF mutation-
associated gene methylation, we used 186 promoter regions
that did not bind H3K27me3 in ES cells representing 125
genes after exclusion of duplicates and annotation by
Panther 6.0. We found five significantly enriched pathways
(P < 0.01) containing 13 unique genes (Table 2).
With seven genes, the Wnt pathway contained the most
BRAF mutation-specific methylation changes (Table 2).
However, the tumor/normal log2 ratios (Figure 2) of
AXIN1, CREBBP, GSK3A, and NKD2 in the BRAF wild-
type samples were low (−0.26 median, 0.12 standard devi-
ation) compared with those in the BRAF mutated samples
(−0.02 median, 0.12 standard deviation). While this could
indicate tumor hypomethylation in BRAF wildtype sam-
ples compared with normal and BRAF mutated samples,
the high level of chromosomal instability among BRAF
wildtype samples suggests that copy-number loss is the
most plausible explanation. To filter for this phenomenon,
we excluded regions with a log2 ratio below one standard
deviation of the median log2 ratio of all BRAF mutation-
specific regions in the BRAF wildtype group. A significant
increase in the BRAF mutant log2 ratios, compared with
those of the BRAF wildtypes, indicates BRAF mutation-
specific hypermethylation in these colon cancer samples
(Figure 2). After filtering out copy-number alterations,
nine of the pathway-associated genes remained (SMO,
FOXB1, FOXB2, FOXD3, CCND1, GNG4, LEF1, MTERF,
TAF7) and the PI3 kinase pathway was the only statisti-
cally significant enriched (P = 0.005) pathway. Interest-
ingly, besides promoter methylation of PI3 kinase
pathway-associated forkhead box (FOX) genes, we identi-
fied promoter methylation of three other FOX transcrip-
tion factors: FOXA1, FOXC1, and FOXF1. However, these
promoters were bound by H3K27me3 and were excluded
from our pathway analysis.n colorectal cancer with chromatin marks in ES cells
K27me3 P CTCF P H3K4me3 P
(31.7%) 0 379 (21.4%) 0 711 (40.2%) 0.000,012
6 (11%) 10,137 (33.3%) 13,835 (45.5%)
(22.6%) 0 183 (24.4%) 0.000,001 300 (40.1%) 0.004,6
8 (11.9%) 10,333 (32.9%) 14,246 (45.3%)
(23.7%) 0 195 (25.7%) 0.000,035 169 (22.3%) 0
7 (11.8%) 10,321 (32.8%) 14,377 (45.8%)
Table 2 Pathways enriched for BRAF mutation-associated promoter methylation after exclusion of ES cell H3K27me3
binding promoter regions
BRAF mutation-specific promoters (125) Associated genes Expected hitsa Hits Pb
Hedgehog signaling pathway SMO; GSK3Ac; CREBBPc 0.16 3 0.000561
PI3 kinase pathway FOXB1; FOXB2; FOXD3; CCND1; GSK3Ac 0.72 5 0.000849
Insulin/IGF pathway-protein kinase B signaling cascade FOXB1; FOXB2; FOXD3; GSK3Ac 0.56 4 0.00252
Wnt signaling pathway NKD2c; GNG4; CCND1; GSK3Ac; CREBBPc; AXIN1; LEF1 1.99 7 0.00405
Transcription regulation by bZIP transcription factor MTERF; CREBBPc TAF7 0.33 3 0.00471
aExpected hits: expected number of hits by chance in the reference gene list; bP values of the binomial test between the BRAF mutation-specific gene list and the
reference gene list; c targets with low tumor/normal log2 ratios in the BRAF wildtype group, suggesting that additional mechanisms, such as genomic loss, may
play a role.
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FOX gene promoter hypermethylation in patient samples
was validated by bisulfite sequencing analysis (BSA). For
FOXB2 and FOXF1, which were found to be hypermethy-
lated in BRAFmutated tumors compared with BRAF wild-
types, DNA methylation was validated using BSA. Bisulfite
sequencing analysis was also attempted for FOXD3 but
was unsuccessful, possibly as a result of the high guanine-
cytosine (GC) content [22]. For both promoters, hyper-
methylation in BRAF mutant tumors was confirmed
(Figure 3A and B). Methylation levels in normal tissue
were below 8% and subtracted from the methylation levels
in the corresponding tumors. The average methylation per
sample for BRAF mutated tumors was significantly higher
than that in BRAF wildtype tumors (Figure 3C, FOXB2
P = 0.0075, FOXF1 P = 0.001).
DNA methylation and gene expression
For a subset of nine tumor-normal pairs, the expression of
FOXB2, FOXD3, and FOXF1 was determined using real-
time reverse-transcription PCR (RT-qPCR). Only two
tumors (both BRAF wildtype) had detectable levels of
FOXB2 expression, and an additional three samples showed
no detectable FOXB2 expression in either tumor or normal
tissue. FOXD3 expression was detected in all but one of the
normal tissue samples, and in three BRAF wildtype tumor
samples. A decrease in FOXF1 expression was observed in
all tumors except for sample 57. Next, we compared
the tumor/normal expression ratios with the methylation
measured by BSA (FOXB2 and FOXF1) or array (FOXD3)
(Figure 4). FOXB2 showed loss of expression in tumors, in-
dependent of methylation status. Expression of FOXF1 was
repressed in all tumors. In BRAF mutated tumors there
appeared to be a negative correlation between DNA methy-
lation and expression. The tumors with FOXD3 hyper-
methylation showed no detectable FOXD3 expression,
suggesting methylation-related silencing.
Discussion
In this study, we extended the number of screened CpG
loci compared with previous studies performed in con-
text of BRAF mutations to identify new BRAF mutation-specific methylation changes in colorectal cancer. We
validated hypermethylation of forkhead box transcription
factors FOXB2 and FOXF1 in BRAFV600E tumors. Add-
itionally, repression of FOXD3 gene expression in
tumors could be related to promoter hypermethylation.
The association between DNA methylation and activat-
ing BRAF mutations in colon cancer has been identified in
several studies [2-8]. Here, we attempted to identify add-
itional targets of BRAF mutation-specific DNA methyla-
tion that could provide a favorable context, either to
obtain a BRAF mutation or to attain the full potential of
RAS-RAF-MEK-induced proliferation provided by this ac-
tivating mutation. Identified targets of promoter methyla-
tion showing pre-marking by H3K27me3 in ES cells were
excluded, to filter out methylation changes with minimal
expected effects on transcription and thereby tumorigen-
esis [17]. We showed high levels of overlap between
CIMP- and BRAF mutation-specific methylation changes,
which remained after filtering out pre-marked loci. Al-
though Rada-Iglesias et al. [17] showed a higher pre-
marking of colon cancer-specific DNA methylation by
H3K27me3 binding in normal colon epithelium compared
with ES cells, we were restricted to using ES cell data,
owing to the incompatibility between data formats in our
analyses. Interestingly, the promoter region of MLH1,
found methylated in both a CIMP- and BRAF mutation-
specific manner, was not filtered out. Therefore, MLH1
promoter methylation, the cause of sporadic MSI colon
cancer, is not established through utilization of a pre-
existing repressive program in ES cells.
The study by Hinoue et al. [2] described BRAF
mutation-specific DNA methylation of 60 genes in a com-
parison of 1,505 CpG sites between 33 BRAF mutated
tumors and 202 BRAF wildtype tumors. The identification
of promoter methylation of the mediator of BRAFV600E-
induced senescence, IGFBP7, led them to suggest that this
epigenetic silencing provides a favorable context for the
acquisition of BRAF mutations [2,23]. Despite differences
in experimental techniques and coverage, 10 genes over-
lapped with our set of BRAF mutation-specific methylated
regions, including the RAS-RAF hyperactivation-asso-
ciated BMP3, receptor kinases EPHA3 and FLT3 as well as
Figure 2 Scatter plots for nine unique genes with BRAF mutation-specific promoter methylation causing pathway enrichment. The y
axis represents the tumor/normal log2 ratio for the median probe per region. Sample IDs are given below the x axis with BRAF wildtypes on the
left of the black line and BRAF mutants on the right. Median log2 ratios and standard deviations (dotted lines) for the BRAF wildtype and BRAF
mutant groups are given in dark green.
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was found for the mediator of RAS-RAF oncogene-induced
senescence, IGFBP7, despite coverage of the IGFBP7 pro-
moter CpG island with two fragments in our assay. Lack of
overlap between these studies may be a consequence of dif-
ferent experimental methods as well as of different patient
cohorts. Additionally, BMP3 and EPHA3 were pre-marked
by H3K27me3 in our analysis suggesting minimal impact
on gene expression and tumorigenesis.We initially identified enrichment of five cancer-
associated pathways by BRAF mutation-specific pro-
moter methylation of nine unique genes. Our analysis
took into account copy-number changes and filtered for
this, as this could improve the reproducibility of differ-
ential methylation hybridization (DMH) based assays
[24,25]. After exclusion of these loci, the PI3 kinase
pathway was the only pathway enriched in our analysis.
Among the four genes enriched in this pathway were the
Figure 3 Tumor hypermethylation of FOXB2 and FOXF1. (A, B) Bisulfite sequence results for 12 BRAF wildtype tumors and 8 BRAF mutant
tumors, separated by the horizontal red line. Schematic display of the BSA region with CpG locations therein shown on top (blue). Sample IDs are
given on the 5' end of the BSA region. Each circle depicts a CpG. Color code: gray = ND, white = 0% to 20%, yellow = 20% to 40%, orange = 40%
to 60%, red > 60% methylation. (C) Boxplot showing average methylation percentage over all detected CpGs in BRAF wildtype and BRAFV600E
tumors for FOXB2 (left) and FOXF1 (right). The box indicates the 25 and 75 percentiles, with the median shown in bold. Upper and lower outliers
are shown as red and purple asterisks, respectively. (D) Schematic display of FOXB2 (top) and FOXF1 (bottom) loci depicting the location of the
BSA regions in relation to MseI fragments detected on the Agilent array (significant fragments marked red, not significant as black). CpG islands
are shown in green, and the BSA region is shown in blue.
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A recent study described FOXD3 as a TP53 and
CDKN1A/p21cip1-dependent negative cell cycle regula-
tor, which is suppressed by activated BRAF in melanoma
cells [26]. Downregulation of FOXD3 levels by promoter
methylation in colon cancer might provide a favorable
setting for either acquisition of a BRAF mutation or pro-
liferation by RAS-RAF-MEK over-activation, similar to
IGFBP7 [2].
Interestingly, the FOXO transcription factors have
also been described as mediators of CDKN2A/p21cip1-
dependent BRAF-induced senescence, indicating that mul-
tiple FOX genes are involved in this process [27]. Weidentified additional FOX genes with BRAF mutation-
specific promoter methylation that were excluded from the
pathway analysis as they were pre-marked by H3K27me3 in
ES cells: FOXA1, FOXC1, and FOXF1. However, the pro-
moters of these genes were also pre-marked with H3K4me3
indicating possible tissue-specific expression. All three are
targets of inactivation in breast cancer and both FOXC1
and FOXF1 are subjected to promoter methylation [28-30].
Most intriguing is the description of FOXF1 as an inducer
of G1-S and S-G2 cell cycle arrest, indicating a possible role
in oncogene-induced senescence in breast cancer [29]. Our
finding that FOXF1 was downregulated in the BRAF
mutated cohort suggests that this gene might also play a
Figure 4 Relation between methylation and expression. Tumor/
normal expression ratios (y axis) were plotted against the average
DNA methylation measured by bisulfite sequence analysis for FOXB2
(A) and FOXF1 (B), and the methylation log2 ratio measured by CpG
array for FOXD3 (C). BRAF mutant samples are shown in red,
wildtype samples in black.
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However, additional research is required to determine the
role of these FOX genes in colon cancer-associated onco-
gene-induced senescence and the impact of their promoter
methylation on this mechanism. Finally, research into the
sequence of such events is required to provide a better
insight in the association between activating BRAF muta-
tions and DNA methylation in colon cancer.Conclusions
In this study, we identified BRAF mutation-specific hyper-
methylation of CpG regions by DMH on high-density
oligonucleotide microarrays. We found enrichment of sev-
eral cancer-related pathways, including the PI3 kinase and
Wnt signaling pathways. We validated differential methyla-
tion of forkhead box (FOX) transcription factors and found
methylation-dependent silencing of FOXD3. By both
extending the number of screened loci and filtering out
genes pre-marked by H3K27me3, we identified new targets
of BRAF mutation-specific methylation that could provide
a favorable context to either obtain a BRAF mutation or to
attain the full potential of this activating mutation.
Availability of supporting data
The data set supporting the results of this article is avail-
able in the Gene Expression Omnibus (GEO) repository
under accession number GSE39334.
Materials and methods
Patient material
From anonymized tumor and normal fresh-frozen colon
mucosa samples obtained from patients who underwent
surgery between 2002 and 2005 at the Leiden University
Medical Center (Leiden, The Netherlands) or at the
Rijnland Hospital (Leiderdorp, The Netherlands), a cohort
containing a high number of CIMP-positive patients
was selected. Age, sex, histology, microsatellite instability,
and BRAFV600E status for the 19 patients used for
the array profiling are listed in Additional file 3. Prior to
DNA isolation, frozen sections were micro-dissected to
minimize the presence of normal epithelium and stromal
cells. To correct for age-dependent methylation, we used
normal mucosa, distant from the tumor, from the same
individuals. The patients’ DNA was isolated by phenol
and chloroform extraction and ethanol precipitation
from 10 to 20 sections of 30 μm. This process yielded
10 to 50 μg of DNA. This study was approved by the
Medical Ethics committee of the LUMC (protocol P01-
019). Cases were analyzed following the medical ethical
guidelines described in the Code Proper Secondary Use of
Human Tissue established by the Dutch Federation of
Medical Sciences.
BRAF mutation analysis
BRAFV600E mutations were detected using flanking pri-
mers that have been previously described [31]. The pro-
ducts of the PCR were purified with the QIAquick PCR
Purification kit (#28106, Qiagen). Sequencing was per-
formed at the Leiden Genome Technology Center (LGTC,
Leiden, The Netherlands) using an ABI 3730 xl (Applied
Biosystems). Mutational analysis was performed using
Mutation Surveyor (SoftGenetics LLC). Results are sum-
marized in Additional file 3.
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Differential methylation hybridization was performed
according to Yan et al. [25] DNA (500 ng) was digested
with MseI, ligated to linkers, and sequentially digested
with two methylation-sensitive restriction enzymes
(HpaII #R0171 and BstUI #R0518, New England Biolabs).
Digested linker-ligated DNA was used as a template for
PCR amplification (20 cycles) and coupled to fluorescent
dyes. Cy5- or Cy3-labeled amplicons, representing methy-
lated DNA fragments derived from tumor and normal sam-
ples, were co-hybridized to the Agilent 244 k human CpG
island microarrays (#G4492A, Agilent Technologies) in a
dye-swap setup. Detection was done on a G2565BA scanner
(Agilent Technologies) and feature extraction using Feature
Extraction Software version 9.5.3.1 (Agilent Technologies).
Array data analysis
Non-background corrected data were preprocessed by
within-array LOESS normalization followed by between-
array aquantile normalization using limma v3.2.1 [32] in
R2.10.0 [33]. Data were corrected for gene-specific dye
bias using R package dyebias v1.4.0 [34]. Raw data and
preprocessed log2 ratios (tumor versus normal) per probe
are available via the Gene Expression Omnibus (GEO)
under accession number GSE39334. Probes mapping to
the same MseI fragment were expected to show similar
hybridization patterns and not to be independent. There-
fore, we mapped probes to the human genome (UCSC as-
sembly March 2006) cut in silico with MseI. Fragments of
150 to 3,000 bp mapping at least one complete probe
and containing at least one BstUI or HpaII restriction site
(n = 32,171) were selected. In total, 195,625 of the 244,000
array probes (80.2%) mapped to such informative frag-
ments, mostly with 1 or 2 probes per fragment, up to 33.
For statistical analysis and visualization, the median log
ratio per fragment was used to represent the fragment.
Methylation differences between tumor and normal sam-
ples and tumor subgroups were analyzed using a linear
model in limma v3.2.1 [32]. The obtained P values were
corrected for multiple testing [35] and fragments with a
false discovery rate ≤0.01 were selected as significantly dif-
ferentially methylated regions.
MLH1 and CIMP marker methylation
DNA samples (500 ng) were bisulfite converted using the
EZ DNA methylation Gold kit (#D5006 Zymo Research).
For validation of methylation changes, we performed a
methylation-specific PCR on the MLH1 promoter using
primers previously described (Additional file 3) [36].
Methylation of previously described CIMP markers:
MINT1, MINT2, MINT12, MINT31, PRDM2/RIZ1, and
TIMP3 were determined by methylation-specific PCR,
while MINT27 and LRP2/megalin methylation were
determined by Combined Bisulfite Restriction Analysis[6,37]. Using the criteria suggested by Shen et al. [6,37] in-
cluding these methylation markers and mutation status of
BRAF, KRAS, and TP53, tumors were determined to be
CIMP-positive when two or more CIMP1 markers (BRAF
mutation, methylated MLH1, TIMP3, MINT1, PRDM2/
RIZ1), or three or more CIMP2 markers (KRAS mutation,
methylated MINT27, MINT2, MINT31, LRP2/megalin)
were present. Tumors were called CIMP-negative when
two or more CIMP-negative markers (TP53 mutation,
unmethylated MINT27, MINT2, MINT31, MINT1) were
present. This CIMP marker set was previously validated
with the CIMP loci proposed by Weisenberger et al.
[8,38]. Amplifications were carried out in a DNA Engine
Dyad Peltier Thermal Cycler (Bio-Rad) using AmpliTaq
Gold PCR buffer and enzyme (#4317742 Invitrogen).
Amplified bands were visualized on a 2% agarose gel.
Bisulfite sequencing analysis
Bisulfite conversion was performed on 200 ng of DNA using
the EZ DNA methylation Gold kit and eluted in 15 μl Milli-
Q purified water. The PCR amplification was performed
using primers designed using MethPrimer (Additional file 5)
[39]. The PCR reaction mixture contained 1× iQ SYBR
green supermix (#170-8884, Bio-Rad), 1 μl of the bisulfite-
converted DNA and 5 nmol of forward and reverse primer.
The PCR products were purified using the MinEluteW 96
UF PCR Purification kit (#28051, Qiagen) and sent for se-
quencing at Macrogen (Macrogen, Europe). Sequence align-
ment and quantification of methylation was performed
using ESME (Epigenomics Inc.) [40]. Statistical significance
of hypermethylation in BRAFV600E tumors was determined
using a one-sided Mann–Whitney test.
Gene expression analysis
Gene expression of FOXB2, FOXD3, and FOXF1 was
determined in nine pairs of tumor and normal tissue of
which RNA was available. cDNA was synthesized using 1
to 2 μg RNA, 50 ng oligo-dT, 1.6 μg random primer,
1 mM dNTPs, 5U AMV-RT transcriptase, and 10 U RNa-
sin (#M5108 and #N2615, Promega). Gene expression
was determined using TaqMan Gene Expression Assays
(Applied Biosystems). Gene expression was normalized
with CPSF6 and HNRNP [41], which were amplified using
0.8 pmol forward and reverse primer in a 1× iQ SYBR
green supermix (#170-8884, Bio-Rad). For FOXB1, FOXB2,
and FOXD3, 2 μl of 125× diluted cDNA was amplified in a
mix containing 1× iQ supermix (#170-8862, Bio-Rad) and
1× TaqMan assay (#Hs00247213_s1, #Hs02386300_s1,
Hs00255287_s1, Hs00230962_m1, Applied Biosystems).
All qPCRs were performed in duplicate.
Exploratory data analysis
Differentially methylated regions were compared with
publicly available data containing chromosomal regions
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http://www.clinicalepigeneticsjournal.com/content/5/1/2identified in chromatin immunoprecipitation using anti-
bodies against H3K27me3, H3K4me3, CTCF, and SUZ12
in ES cells followed by high-throughput sequencing
[42-44]. By using the sqldf R package (version 0.3-5), we
determined overlap of at least 20 bp between CpG regions
represented on the array and these regions. Enrichment of
chromatin domains among the differentially methylated
regions was calculated by χ-squared test. Functional
annotation clustering was performed in Panther 6.0 [45].
Filtering of the differential methylation datasets by
H3K27me3 in ES cells using the dataset from Zhao et al.
[44] was performed in R using the sqldf package.
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